Dear Friends,

"I don't have time; I can't keep track of anything"—this is the problem cited by 75% of my friends.

Think about the job you currently hold: you spent years laying the groundwork to get there, and you continue to dedicate time and effort to remain in that role, earn a higher salary, and advance to better positions. All that effort is ultimately to generate income, isn't it?

So, how is it that there is no time left for the very act of growing the wealth you’ve earned? I leave the answer to that question to each person's conscience. Just ask your mobile phone where your time is being spent; it will give you a better answer than you could yourself.

I had previously posted about a friend who made money by trading very safely in MTF (Margin Trading Facility).

This post is about a friend who handles GTT (Good Till Triggered) orders exceptionally well.
He works in the medical field and also takes care of a teenage child.
He is my senior in both the Facebook community and the stock market.
He skillfully handles both fundamental and technical analysis.
He analyzes fundamental data, calculates the right price to buy a promising company's stock, places a GTT order, and then goes about his work. His recent GTT order was triggered at 4440. In a sector where many have burned their fingers, he has made a 13.85% profit in just nine trading days. This was his first entry for this stock; he has further GTT orders set at lower price points.

In May, he sold a portion of his holdings in *Carysil* after making a 105% profit, while retaining two-thirds of the shares. Generally, he selects stocks that have the potential to rise by at least 100%. He has never once asked me, "How is this stock doing?" or "What is your view on it?" I, on the other hand, have occasionally asked him about the fundamentals of certain stocks; I recently asked him about *Fermenta*.

His reply:
"Good Evening Sister,
I seem to recall reading somewhere last week that one should keep an eye on *Fermenta Biotech*." I took a look at it after you mentioned it.

They recently secured a patent for vegan Vitamin D3; capital expenditure (Capex) is being funded through internal accruals, and rising Vitamin D3 prices are positive developments that have brought this stock into the spotlight.

Promoter holding is strong; even within the retail segment, the stock is largely held by ESOP holders and related parties. I believe the free float is low.

A review of the financials and presentations shows a strengthened balance sheet.

Margin fluctuations make profits cyclical. Future growth hinges on Capex implementation, production execution, and future demand.

While their market is well-diversified, their flagship Vitamin D3 product faces stiff competition from China and Germany.

Cash conversion needs improvement, as does the issue of piled-up inventory.

High short-term borrowings are a concern for me.

The lack of FII/DII participation is also a red flag, especially for a company that has been listed for a long time. The stock was permitted to trade on the NSE only last quarter; it might soon be fully listed there. I generally avoid companies listed solely on the BSE. It seems the management has decided to increase their visibility now—perhaps to pump up the price and later offload a percentage of their shares. I am just being cautious and apprehensive.
To me, it isn't an investment-grade stock; it might be considered for the short term—riding the wave as long as Vitamin D3 prices remain high.

His approach seems quite impressive.

He regularly conducts a thorough analysis before buying such stocks and has a clear plan regarding the price point and quantity as well. 

Overall, he manages his journey so so beautifully by analyzing stocks and trading via GTT (Good Till Triggered) orders during his spare time.

These are all without disrupting his full-time job or compromising the time he dedicates to his child's constructive purposes.